|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02666 UNI MEDICAL
Nominal 
4.700 -0.035 (-0.739%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 7,100,797 | -6.331% | 14,939,517 | 13,663,485 | 13,650,203 | 12,073,172 |
| Cost of Sales | (4,597,895) | -7.629% | (9,909,481) | (9,071,645) | (9,078,344) | (7,578,878) |
| Gross Profit | 2,502,902 | -3.848% | 5,030,036 | 4,591,840 | 4,571,859 | 4,494,294 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (70,642) | 45.678% | (331,323) | (322,980) | (192,099) | (307,139) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | (519) | (1,624) | (1,154) | |
| Share of Results of Asso. & JCEs | (1,732) | 91.593% | (9,092) | 26,564 | 6,380 | 13,462 | |
| Profit / (Loss) before Taxation | 1,745,906 | 0.264% | 3,019,148 | 2,907,119 | 2,866,213 | 2,703,274 | |
| Taxation | (400,483) | -1.380% | (701,556) | (648,785) | (667,141) | (617,326) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (61,861) | -19.052% | (108,641) | (154,377) | (88,735) | (126,128) | |
| Others | (21,033) | -31.428% | (52,188) | (72,217) | (89,419) | (71,403) | |
| Profit / (Loss) Attributable to Shareholders | 1,262,529 | 2.801% | 2,156,763 | 2,031,740 | 2,020,918 | 1,888,417 | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 13,122 | -24.268% | 27,404 | (4,797) | (45,075) | (38,517) |
| Depreciation & Amortisation | 407,755 | 19.001% | 788,457 | 602,257 | 508,665 | 442,049 |
| Directors' Emoluments | -- | -- | 8,215 | 8,786 | 13,785 | 14,631 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 63.000 | -3.077% | 113.000 | 107.000 | 107.000 | 100.000 |
| DPS (cts) | 0.000 | -- | 31.809 | 32.300 | 31.740 | 29.788 |
| Dividend Payout Ratio (%) | -- | -- | 28.149% | 30.187% | 29.664% | 29.788% |
| Cash flow per share ($) | -- | -- | 3.027 | 0.602 | 2.640 | 1.074 |
| NBV per share ($) | 9.911 | -- | 9.572 | 9.058 | 8.248 | 7.351 |
| Remarks: | Real time quote last updated: 09/09/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 1,262,529 |
| %Change | 2.801% |
| EPS / (LPS) | RMB 0.630 |
| NBV Per Share (¥) | RMB 9.911 |